Immunomodulation by memantine in therapy of Alzheimer's disease is mediated through inhibition of K(v)1.3 channels and T cell responsiveness

Memantine is approved for the treatment of advanced Alzheimer's disease (AD) and reduces glutamate-mediated neuronal excitotoxicity by antagonism of N-methyl-D-aspartate receptors. In the pathophysiology of AD immune responses deviate and infectious side effects are observed during memantine th...

Descripción completa

Detalles Bibliográficos
Autores principales: Lowinus, Theresa, Bose, Tanima, Busse, Stefan, Busse, Mandy, Reinhold, Dirk, Schraven, Burkhart, Bommhardt, Ursula H.H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288222/
https://www.ncbi.nlm.nih.gov/pubmed/27462773
http://dx.doi.org/10.18632/oncotarget.10777

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288222/
https://www.ncbi.nlm.nih.gov/pubmed/27462773
http://dx.doi.org/10.18632/oncotarget.10777

Ejemplares similares